Physician profile
Mark J Gipson
NPI 1629070511
$726.70
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $250 · 2021: $33.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $161.35 | 2019-2020 | |
| Sanofi Pasteur INC. | $63.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.40 | 2019-2020 | |
| Novo Nordisk INC | $60.20 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $58.42 | 2019-2020 | |
| Shire North American Group INC | $54.59 | 2019 | |
| Cranial Technologies, INC | $39.45 | 2019-2021 | |
| Lilly USA, LLC | $38.58 | 2019 | |
| Amgen INC. | $37.16 | 2019 | |
| Merck Sharp & Dohme LLC | $36.04 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $20.44 | 2019 | |
| Abbott Laboratories | $18.90 | 2021 | |
| Valeritas, INC. | $14.70 | 2019 | |
| Genentech USA, INC. | $14.28 | 2020 | |
| Amarin Pharma, INC. | $13.83 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.51 | 2019 | |
| Ibsa Pharma INC. | $10.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.